NCT06815354Active, not recruiting
Comprehensive Assessment of Cancer Theranostic Response
Comprehensive Assessment of Cancer Theranostic Response; Investigating the Intent to Change Treatment Decisions Based on TRAQinform Theranostics
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 4 Feb 2025
- Start date
- 2 Dec 2024
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- AIQ Solutions
- Diseases
- Prostate cancer
- NCT number
- NCT06815354
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From 2 Dec 2024 to the primary completion date, 31 Aug 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial.
Who the study is looking for
- Age 18 years or older and willing and able to provide informed consent.
- Diagnosis of metastatic prostate cancer.
- Planned to start 177Lu-PSMA (Pluvicto).
- Ability to tolerate two 68Ga-PSMA or 18F-DCFPyL PET/CT imaging procedures. One at baseline and at 12 weeks of 177Lu-PSMA (Pluvicto) treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at screening.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Weill Medical College of Cornell Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.